Skip to main content
Year archive

FARON PHARMACEUTICALS OY — 2025 filings

All 65 regulatory filings released by FARON PHARMACEUTICALS OY (FARN) in 2025, sourced directly from the official regulator.

65 Filings
2025 Period
2025 filings (65)
Filing Released Lang
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer
Regulatory Filings
2025-12-22 English
Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
Regulatory Filings
2025-12-17 English
Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement
Capital/Financing Update
2025-12-11 English
Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile
Regulatory Filings
2025-12-08 English
Faron Pharmaceuticals Ltd: Holding(s) in Company
Major Shareholding Notification
2025-12-04 English
Faron Pharmaceuticals Ltd: Registration of New Shares
Share Issue/Capital Change
2025-12-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
Share Issue/Capital Change
2025-12-03 English
Faron Pharmaceuticals Ltd: Grant of Options
Director's Dealing
2025-12-02 English
Faron Pharmaceuticals Ltd: Appointment of CFO
Board/Management Information
2025-12-01 English
Faron’s Financial Calendar for 2026
Report Publication Announcement
2025-11-27 English
INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT
Capital/Financing Update
2025-11-24 English
Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy
Regulatory Filings
2025-11-04 English
Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment
Legal Proceedings Report
2025-11-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
Share Issue/Capital Change
2025-10-28 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2025-10-21 English
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients
Earnings Release Q4 2025
2025-10-20 English
Faron Pharmaceuticals Ltd: Registration of New Shares
Share Issue/Capital Change
2025-10-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
Share Issue/Capital Change
2025-10-03 English
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity
Director's Dealing
2025-09-19 English
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
Interim / Quarterly Report H1 2025
2025-09-12 English
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
Interim / Quarterly Report H1 2025
2025-08-27 English
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
Report Publication Announcement
2025-08-19 English
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA
Legal Proceedings Report
2025-08-18 English
Faron Pharmaceuticals Ltd: Holding(s) in Company
Major Shareholding Notification
2025-08-08 English
Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted
Regulatory Filings
2025-08-08 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
Capital/Financing Update
2025-08-07 English
Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%
Earnings Release Q3 2025
2025-08-06 English
FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025
Regulatory Filings
2025-07-30 English
Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025
Regulatory Filings
2025-07-09 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing
2025-07-02 English
Faron Pharmaceuticals Ltd: Director/PCA Dealing
Director's Dealing
2025-06-30 English
Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action
Regulatory Filings
2025-06-30 English
Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025
Regulatory Filings
2025-06-12 English
Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation
Director's Dealing
2025-06-05 English
Faron Pharmaceuticals Ltd: Registration of New Shares
Share Issue/Capital Change
2025-06-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
Capital/Financing Update
2025-06-03 English
Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025
Regulatory Filings
2025-06-02 English
Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology
Regulatory Filings
2025-05-30 English
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
Share Issue/Capital Change
2025-05-27 English
Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies
Regulatory Filings
2025-05-27 English
Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab
Regulatory Filings
2025-05-23 English
Faron Appoints Ralph Hughes as Chief Business Officer (CBO)
Board/Management Information
2025-05-21 English
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress
Regulatory Filings
2025-05-15 English
Faron Pharmaceuticals Ltd: Grant of Options
Director's Dealing
2025-05-14 English
Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session
Earnings Release Q2 2025
2025-05-12 English
Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025
Regulatory Filings
2025-04-24 English
Holding in Company
Major Shareholding Notification
2025-04-17 English
Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome
Regulatory Filings
2025-04-15 English
Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million
Capital/Financing Update
2025-04-03 English
Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress
Regulatory Filings
2025-03-27 English
Board Changes
Board/Management Information
2025-03-21 English
Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM
AGM Information
2025-03-21 English
Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected
AGM Information
2025-03-20 English
FDA Grants Orphan Drug Designation
Regulatory Filings
2025-03-03 English
Notice of Annual General Meeting
AGM Information
2025-02-28 English
Positive EMA Opinion on Orphan Drug Designation
Regulatory Filings
2025-02-27 English
Annual Report 2024 published
Report Publication Announcement
2025-02-27 English
Financial Statement 1 January to 31 December 2024
Annual Report FY 2024
2025-02-27 English
Notice of Financial Statement and Annual Report
Report Publication Announcement
2025-02-19 English
Holding(s) in Company
Major Shareholding Notification
2025-02-14 English
Change of Broker
Board/Management Information
2025-02-11 English
Holding(s) in Company
Major Shareholding Notification
2025-02-06 English
Results of Oversubscribed Placing
Capital/Financing Update
2025-02-06 English
Proposed Issue and Placing
Capital/Financing Update
2025-02-05 English
Final Patient Identified for BEXMAB Phase II Study
Earnings Release Q1 2025
2025-01-31 English